Management is evolving USANA from a legacy direct selling business into a modern science-driven nutritional products company through an omnichannel platform. Consolidated net sales growth of 4% at the midpoint for fiscal 2026 is primarily attributed to the expansion of venture brands Hiya and Rise Wellness. The core nutritional business is showing signs of stabilization despite year-over-year declines, with a focus on moving with greater speed and brand relevancy. Operational efficiency is being tar ...

Core Insights - Abbott reported strong financial results for Q4 2025, with total worldwide sales reaching $11.459 billion, a 4.4% increase from Q4 2024 [28] - The company achieved double-digit earnings per share growth, with adjusted diluted EPS of $1.50, reflecting a 12% increase [5] - Abbott's full-year 2025 sales totaled $44.328 billion, marking a 5.7% increase compared to 2024 [28] Financial Performance - Q4 2025 sales increased 4.4% on a reported basis and 3.0% on an organic basis, with a 3.8% increase when excluding COVID-19 testing-related sales [5][28] - Full-year 2025 GAAP diluted EPS was $3.72, while adjusted diluted EPS was $5.15, reflecting a 10% growth [5][28] - Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80 [5][22] Segment Performance - In Q4 2025, Nutrition sales decreased by 8.9% on a reported basis and 9.1% on an organic basis, primarily due to lower sales volumes [9][10] - Diagnostics sales in Q4 2025 were $2.457 billion, a decrease of 2.5% on a reported basis and 3.6% on an organic basis [12][28] - Medical Devices sales increased by 12.3% on a reported basis and 10.4% on an organic basis, driven by strong growth in Electrophysiology and Diabetes Care [19][20] Strategic Developments - Abbott announced an agreement to acquire Exact Sciences, positioning the company to enter the cancer diagnostics market [5] - The company received FDA approval for its Volt™ PFA System and CE Mark for its TactiFlex™ Duo Ablation Catheter, enhancing its Electrophysiology portfolio [5][10] Dividend Information - Abbott declared a quarterly dividend of $0.63 per share, marking the 408th consecutive quarterly dividend and reflecting a commitment to returning value to shareholders [24]

Core Viewpoint - Abbott is set to announce its fourth-quarter 2025 financial results on January 22, 2026, before market opening, followed by a live webcast of the earnings conference call [1] Group 1: Financial Announcement - The financial results announcement will occur on January 22, 2026, before the market opens [1] - A live webcast of the earnings conference call will take place at 8 a.m. Central time (9 a.m. Eastern) [1] - The archived edition of the call will be available later that same day [1] Group 2: Company Overview - Abbott is a global healthcare leader with a focus on helping people live fully at all stages of life [2] - The company's portfolio includes technologies in diagnostics, medical devices, nutritionals, and branded generic medicines [2] - Abbott employs 114,000 colleagues and serves customers in over 160 countries [2]

Core Viewpoint - Abbott has announced a 6.8% increase in its quarterly common dividend to 63 cents per share, marking its 54th consecutive year of dividend growth and the 408th consecutive quarterly dividend payment since 1924 [1][4]. Group 1: Dividend Information - The quarterly dividend payout has increased more than 70% since 2020 [1][4]. - The cash dividend is payable on February 13, 2026, to shareholders of record as of January 15, 2026 [1]. Group 2: Company Background - Abbott is a global healthcare leader with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries [3]. - Abbott is a member of the S&P 500 Dividend Aristocrats Index, which includes companies that have increased dividends annually for at least 25 consecutive years [2].

Core Insights - Abbott's third-quarter results for 2025 show a total worldwide sales increase of 6.9% to $11.369 billion compared to $10.635 billion in the same quarter of 2024 [23] - The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30, reflecting a 7.4% increase from the previous year [7][24] - Abbott reaffirms its full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales [17] Financial Performance - Total reported sales for the third quarter were $11.369 billion, with U.S. sales at $4.299 billion and international sales at $7.070 billion [4] - The organic sales growth was 5.5%, or 7.5% when excluding COVID-19 testing-related sales [7] - Year-to-date sales for the first nine months of 2025 reached $32.869 billion, a 6.1% increase from $30.976 billion in the same period of 2024 [24] Segment Performance - Nutrition segment sales for Q3 2025 were $2.153 billion, with U.S. sales declining by 6.5% and international sales increasing by 13.3% [6][9] - Diagnostics segment reported sales decreased by 6.6% to $2.253 billion, with a notable decline in COVID-19 testing sales from $265 million in Q3 2024 to $69 million in Q3 2025 [10][11] - Medical Devices segment sales increased by 14.8% to $5.448 billion, driven by strong growth in Diabetes Care and other areas [15][16] Guidance and Future Outlook - Abbott has narrowed its full-year 2025 adjusted diluted EPS guidance range to $5.12 to $5.18, indicating double-digit growth at the midpoint [7][17] - The company received regulatory approvals for new products, including TriClip and an expanded indication for the Navitor TAVI system, which are expected to contribute to future growth [7] Dividend Information - Abbott declared a quarterly dividend of $0.59 per share, marking the 407th consecutive quarterly dividend, with a history of increasing dividends for 53 consecutive years [19]

Core Insights - The article emphasizes the importance of service as a means to enhance emotional wellness, particularly for leaders, highlighting that serving others can lead to emotional regulation and focus on what truly matters [1][2][3] Company Overview - USANA Health Sciences (NYSE: USNA) is recognized as a global leader in health and wellness products, emphasizing the significance of social wellness in building a successful business since its founding in 1992 [9] Leadership and Emotional Wellness - Kevin Guest, executive chairman of USANA, advocates that giving back is essential for leaders, as it fosters emotional strength through outward compassion [2][3] - Guest shares that service acts can disrupt negative thinking, restore clarity, energize the giver, reshape emotional patterns, ground identity, and strengthen team bonds [7] Philanthropy and Community Impact - All proceeds from Guest's book "All the Right Reasons" benefit the USANA Foundation, which has provided over 112 million meals to impoverished children and families [8]

Core Insights - Abbott reported strong financial results for the second quarter of 2025, with total worldwide sales reaching $11.142 billion, a 7.4% increase compared to the same period in 2024 [28][29] - The company achieved high single-digit organic sales growth and double-digit growth in earnings per share (EPS), indicating robust operational performance [2][5] - Abbott anticipates continued momentum into 2026, projecting full-year 2025 organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales [22] Second Quarter Business Overview - Total reported sales for the second quarter were $11.142 billion, with U.S. sales at $4.276 billion and international sales at $6.866 billion [4] - Organic sales growth was reported at 6.9%, or 7.5% when excluding COVID-19 testing-related sales [5][6] - The company’s gross margin improved to 52.7% of sales, with an adjusted gross margin of 57.0%, reflecting a 100 basis point increase [5] Segment Performance Nutrition - Worldwide Nutrition sales increased by 2.9% on a reported basis and 3.4% on an organic basis in the second quarter [8] - Adult Nutrition drove growth, with global sales rising 6.1% on a reported basis, supported by brands like Ensure® and Glucerna® [8] Diagnostics - Total Diagnostics sales decreased by 1.0% on a reported basis and 1.4% on an organic basis, impacted by a decline in COVID-19 testing-related sales [10][11] - COVID-19 testing sales were $55 million in the quarter, down from $102 million in the previous year [11] Established Pharmaceuticals - Established Pharmaceuticals sales increased by 6.9% on a reported basis and 7.7% on an organic basis in the second quarter [14][15] Medical Devices - Worldwide Medical Devices sales grew by 13.4% on a reported basis and 12.2% on an organic basis, with significant contributions from Diabetes Care and Heart Failure segments [18][19] Financial Guidance - Abbott projects full-year 2025 adjusted diluted EPS to be between $5.10 and $5.20, reflecting double-digit growth at the midpoint [22] - The company also expects an adjusted operating margin of approximately 23.5% of sales for the full year [22] Dividend Declaration - Abbott declared its quarterly dividend of $0.59 per share, marking the 406th consecutive quarterly dividend [24]

Dividend Declaration - Abbott's board of directors declared a quarterly common dividend of 59 cents per share, marking the 406th consecutive quarterly dividend since 1924 [1] - The cash dividend is payable on August 15, 2025, to shareholders of record at the close of business on July 15, 2025 [1] Dividend Growth - Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years [2] Company Overview - Abbott is a global healthcare leader with a portfolio that includes diagnostics, medical devices, nutritionals, and branded generic medicines, serving people in over 160 countries with 114,000 employees [3]